Dermatology

NCI-CCC Tumor Board Question

These are questions being discussed by academics at NCI-Cancer Centers

Questions discussed in this category

How extensive of a workup do you do for systemic AL amyloidosis for a patient with a resected amyloidoma, localized AL amyloid deposition in their airway or lungs, who has no other symptoms?

Would you do a 24-hour urine and echocardiogram in all of these patients? Cardiac biomarkers, PT/PTT, or any other such blood tests?

3 Answers available

In which clinical situations, if any, would you use imiquimod for treatment of breast cancer skin metastases?

1 Answer available

Papers discussed in this category

Clinical cancer research : an official journal of the American Association for Cancer Research, 2012-12-15

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.

JAMA oncology, 2017-07-01

Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial.

Haematologica, 2013-01

Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.

The Lancet. Haematology, 2015 May 06

Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.

European respiratory review : an official journal of the European Respiratory Society, 2017 Sep 06

The lung in amyloidosis.

Mayo Clinic proceedings, 2017-06

Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience.

Blood Cancer J, 2022 Sep 14

Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.

Related Topics in Dermatology